Allogeneic mesenchymal stromal cell injections for knee osteoarthritis: a review of clinical outcomes.
Johnson S., Boettcher BJ., Korpershoek JV., Hevesi M., Saris DBF., Nagelli CV.
Clinical Trial with a reported sample of 11 on Knee Osteoarthritis, Osteoarthritis, published in Regen Med (2025) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Regen Med (2025)
- Country
- England
- Reported sample size
- 11
- Source database
- PubMed
- PMID
- 41108176
- DOI
- 10.1080/17460751.2025.2572202
Abstract (original English)
Mesenchymal stromal cell (MSC) therapy is an injectable, orthobiologic treatment for patients with knee osteoarthritis (OA). The purpose of this narrative review is to evaluate the literature on allogeneic MSCs used in knee OA patients and to report on clinical outcomes. A comprehensive literature search was performed using the following keywords: osteoarthritis, knee, stem cell transplantation, allogeneic or allogenic, human mesenchymal stem cells, and human mesenchymal stromal cells. There was no restriction on time, and subjective and objective clinical outcomes were reported. A total of 11 ( n = 11) clinical trial studies were included. The most common allogeneic source was adipose tissue (AD-MSCs). Most studies included a control group and included participants with Kellgren-Lawrence grades of II-III or II-IV. The MSC dose used was highly variable. There were no significant adverse safety events. All studies reported an improvement in patient reported outcomes from baseline, with the most common observation being a durable reduction in pain for 6 to 24 months. There were positive effects of AD-MSCs on cartilage imaging in most studies, although outcomes were variable. Allogeneic MSC injections for knee OA resulted in improved OA related symptom scores, are safe, and provided patients with a reduction in pain at long-term follow-up.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisPubMed
Clinical Outcomes of Biologic Therapies for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Studies With ≥12-Month Follow-up.
Meta-analysis on Knee Osteoarthritis, Osteoarthritis, published in Mod Rheumatol (2026) — summary generated from the PubMed abstract.
- 2026
Mod Rheumatol - Level AMeta-analysisEurope PMC
Towards optimized rehabilitation with regenerative therapy: A systematic review and meta-analysis on the effects of cell-based injections for knee osteoarthritis
Meta-analysis on Knee Osteoarthritis, Osteoarthritis, published in Knee Surg Sports Traumatol Arthrosc (2026) — summary generated from the PubMed abstract.
- 2026
Knee Surg Sports Traumatol Arthrosc - Level ASystematic ReviewPubMed
Intra-articular fat grafting for pain relief and functioning improvement in patients with knee osteoarthritis: systematic review.
Systematic Review on Knee Osteoarthritis, Osteoarthritis, published in Disabil Rehabil (2026) — summary generated from the PubMed abstract.
- 2026
Disabil Rehabil - Level ASystematic ReviewPubMed
Research Landscape of Stem Cell Applications in Musculoskeletal Tissue: A Scoping Review.
Systematic Review on Knee Osteoarthritis, Osteoarthritis, published in Cells (2026) — summary generated from the PubMed abstract.
- 2026
Cells - Level AMeta-analysisPubMed
Comparative efficacy of different doses of mesenchymal stem cells derived from different tissue sources for knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials.
Meta-analysis with a reported sample of 602 on Knee Osteoarthritis, Osteoarthritis, Chronic Inflammation, Immune Modulation, published in PeerJ (2026) — summary generated from the PubMed abstract.
- 2026
- n = 602
PeerJ - Level AMeta-analysisEurope PMC
Influence of platelet-rich plasma composition on pain and functional performance in knee osteoarthritis: a systematic review and network meta-analysis
Meta-analysis with a reported sample of 5251 on Knee Osteoarthritis, Osteoarthritis, published in Knee Surg Relat Res (2026) — summary generated from the PubMed abstract.
- 2026
- n = 5251
Knee Surg Relat Res